Research
Hormonal
In adults with obesity, treatment with 36 mg of orforglipron for 72 weeks led to a mean body weight reduction of -11.2%, significantly greater than the -2.1% reduction with placebo (P<0.001).
Orforglipron may be an effective treatment option for weight loss in obese adults.
StrongSupportsmedium confidence
The mean change in body weight from baseline to week 72 was -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo).
Why this rating
Based on a phase 3 randomized controlled trial design.
Source
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Sean Wharton et al. · New England Journal of Medicine · 2025
rct · n=3127Cited 69×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →